Chemical industry in Czech Republic

On‑schedule first production (30 Sept 2026) of 450 MTD weak nitric acid; 12‑hour start‑up, initial 100 t run, ~1,000 t produced and steam export started.

Once‑daily oral GLP‑1 cut MACE vs insulin glargine, lowered A1C by 1.6% at 52 weeks and produced mean weight loss of 8.1 kg with durable effects to 104 weeks.

Net profit USD 1m; sold ammonia distribution and monetized Methanex; OCI Nitrogen impaired and facing margin pressure; held‑for‑sale net cash USD 1.05bn; NNS offer and Orascom deal progressing.

FDA clears once‑weekly basal insulin that reduces injection frequency vs daily therapy; Phase 3 QWINT trials in >3,400 adults showed non‑inferior A1C vs glargine and degludec.

€1bn Europe-wide auction for industrial process-heat decarbonisation; bidding opens early Dec 2026. Supports electrification, renewable heat and SMRs with a fixed premium per tCO2.

SAF reached 1.1 Mt (2.8% share), a near sixfold rise from 2024; supplied at 121 airports, 84% produced in the EU, and 18 Member States host production projects.

Selective growth in electronics, healthcare and mobility; €300–€400m annual investment; PACE to save >€300m/year from 2028; Net Zero by 2045.

Deal via Hy24’s Clean Hydrogen Infrastructure Fund buying Lubmin‑Brandov Assets GmbH & Co. KG; OPAL spans 470 km; northern section converted Dec 2025, full conversion by end‑2030; needs approvals.

Divestment transfers 100% of Lubmin-Brandov Assets GmbH & Co. KG to buyer's Clean Hydrogen Infrastructure Fund; aligns with EU state‑aid remedies and hydrogen conversion timeline for OPAL.

New line supports 580,000 t/y ECOPlanet low-carbon cement; 115,000 t/y calcined clay capacity cuts cement CO2 by ~30% while using local quarry feed.